Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06412458 | IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma | unknown | Phase 1 | 9 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT06412692 | Motivational Interviewing in Adolescents With Epilepsy | unknown | N/A | 72 | Izmir Katip Celebi UniversityOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06412952 | 68Ga-NOTA-RM26 PET/CT in Glioma Patients | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT02661503 | HD21 for Advanced Stages | unknown | Phase 3 | 1,500 | University of CologneOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT06410677 | Changhai Multimodal Esophageal Cancer Cohort(CMECC) | unknown | — | 110 | WangluoweiOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT03337919 | ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma(ANIMATE) | unknown | Phase 2 | 78 | University College, LondonOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT04655118 | Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | unknown | Phase 2 | 121 | Telios Pharma, Inc.INDUSTRY | 13 | May 10, 2024 | clinicaltrials |
| NCT05832320 | Optimum Induction Therapy of Low-risk APL | unknown | N/A | 74 | Peking University People's HospitalOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06409195 | A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers | unknown | Phase 2 | 50 | DermBiont, Inc.INDUSTRY | 1 | May 10, 2024 | clinicaltrials |
| NCT06409221 | VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study | unknown | — | 200 | ConcrINDUSTRY | 1 | May 10, 2024 | clinicaltrials |
| NCT06410040 | A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis | unknown | — | 28 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT01428973 | Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens | unknown | Phase 2 | 200 | University of LiegeOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT04159974 | RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus(RICE) | unknown | Phase 2 | 56 | University of CologneOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT04755920 | SGM-101 in Colorectal Brain Metastases.(SGM-CBM) | unknown | Phase 2 | 10 | Leiden University Medical CenterOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT04814953 | HRQoL Keratinocyte Carcinomas | unknown | — | 2,400 | University Hospital, GhentOTHER | 2 | May 9, 2024 | clinicaltrials |
| NCT05787964 | Immunity to Infection in Healthy Participants and Participants With Cancer(SYS01) | unknown | — | 200 | University Hospital TuebingenOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06251102 | Real-world Ruxolitinib Experience in PV(REVIEW) | unknown | — | 153 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | May 9, 2024 | clinicaltrials |
| NCT06406556 | Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL(ENKTL) | unknown | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06406608 | Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer | unknown | N/A | 20 | Henan Cancer HospitalOTHER_GOV | 1 | May 9, 2024 | clinicaltrials |
| NCT06406660 | Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer | unknown | N/A | 20 | Henan Cancer HospitalOTHER_GOV | 1 | May 9, 2024 | clinicaltrials |
| NCT02509286 | Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus(ESOPEC) | unknown | Phase 3 | 438 | University Hospital Schleswig-HolsteinOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05758610 | A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients | unknown | Phase 1 | 60 | Shengke Pharmaceuticals (Jiangsu) Limited, ChinaINDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT06405035 | Dissecting the Role of MIcrobioMe in gastroEsophageal Tumor: a multIdisCiplinary Longitudinal Study(MIMETIC) | unknown | — | 140 | European Institute of OncologyOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT03292263 | ASCT With Nivolumab in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT05354102 | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 | unknown | Phase 1 | 11 | Biomica Ltd.INDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT05443646 | Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients | unknown | Phase 2 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT05635266 | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives | unknown | — | 20,000 | Sanguine BiosciencesINDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT06115239 | QOL After SURGERY and ADJUVANT Treatment | unknown | — | 200 | University of SalamancaOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06400654 | PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC(NIRVANA) | unknown | — | 100 | European Institute of OncologyOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT00892866 | CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells | unknown | N/A | 877 | GOG FoundationNETWORK | 3 | May 3, 2024 | clinicaltrials |
| NCT01649089 | Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer | unknown | N/A | 224 | GOG FoundationNETWORK | 3 | May 3, 2024 | clinicaltrials |
| NCT03833440 | Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance(PIONeeR) | unknown | Phase 2 | 114 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT04193956 | POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors(POINTING) | unknown | — | 3,500 | University Medical Center GroningenOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT04486781 | A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma | unknown | Phase 2 | 38 | Vasgene Therapeutics, IncINDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT06396143 | Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics Integration | unknown | — | 120 | Zhejiang UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT03466944 | PUMA (Paediatric Osseous Marrow Assessment)(PUMA) | unknown | — | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT04557020 | Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC | unknown | Phase 3 | 200 | Jiangxi Provincial Cancer HospitalOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06252857 | Real-world Evaluation of Diagnostic and Treatment Strategies in Low-Risk Basal Cell Carcinoma(REDT-BCC) | unknown | — | 142 | Maastricht University Medical CenterOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06393335 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research | unknown | Early Phase 1 | 36 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06394427 | Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer | unknown | — | 250 | West China HospitalOTHER | 0 | May 1, 2024 | clinicaltrials |
| NCT04622007 | Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)(KICKSTART) | unknown | Phase 2 | 68 | Effector TherapeuticsINDUSTRY | 3 | Apr 30, 2024 | clinicaltrials |
| NCT05858385 | Predictive Study on Acute Radiation Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients | unknown | — | 700 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06206096 | PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC | unknown | Phase 2 | 40 | Chinese PLA General HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06272656 | Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma | unknown | — | 200 | Hebei Medical University Third HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06391879 | Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma | unknown | — | 300 | Peking University First HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT05458544 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application(LUCIDA) | unknown | Phase 1 / Phase 2 | 26 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05579184 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2(LUCIDA_2) | unknown | Phase 2 | 20 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06252974 | Accurate Diagnosis of the Invasion Depth in ESCC by a Deep Neural Network Analysis of NBI Endoscopy Data | unknown | — | 500 | RenJi HospitalOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT06387238 | Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer | unknown | N/A | 150 | Peking University First HospitalOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT04499339 | A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 38 | Wuerzburg University HospitalOTHER | 3 | Apr 25, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 14, 2024source: clinicaltrials